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Increased levels of an endogenous inhibitor of tissue-
plasminogen activator (t-PA) have been thought to relate
to the genesis of acute myocardial ischemia. To examine
the role of the rapid inhibitor of t-PA, plasma samples
were analyzed from 75 patients with chest pain syndrome
undergoing coronary angiography (mean age 57 years),
24 patients with clinically documented coronary artery
disease (unstable angina, positive exercise stress test or
previous history of myocardial infarction; mean age 58
years) and 15young normal subjects (mean age 26 years).
Plasma t-PA inhibitor levelswere similar in age-matched
patients regardless of the absence or presence (and de-
gree) of coronary artery disease. Plasma t·PA inhibitor
levels correlated significantly with age (r - 0.46, p <
Tissue plasminogen activator (t-PA) has been shown to be
a promising agent in the treatment of coronary artery throm-
bosis associated with acute myocardial infarction (I). A
rapid inhibitor of t-PA has also been identified in human
plasma (2-5), and plasma levels of this inhibitor have re-
centl y been reported to be increased in patients with coro -
nary artery disease (6-8) . Increased plasma levels of the
inhibitor of t-PA might have implications for the pathogen-
esis of coronary artery disea se , because impaired fibrinolysis
has been claimed to participate in the development (8.9)
and genesis of clinical states associated with intravascular
thrombosis. In the present investigation, we measured plasma
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0.005), suggesting an age-dependent decrease in fibrin-
olytic activity. Plasma t·PA inhibitor levels also corre-
lated significantly with serum triglyceride levels (r -
0.60, p < 0.001), but not with coronary risk factors such
as serum cholesterol, diabetes, hypertension , serum uric
acid levels or body weight.
Association of high levels of inhibitor of t·PA with
hypertriglyceridemia may be of importance in the de-
velopment of coronary thrombosis, especially in elderly
patients. Nonetheless, this study does not suggest a
pathogenic role of t·PA inhibitor in coronary athero-
sclerosis.
(J Am Coil Cardiol 1987;9:263-8)
t-PA inhibitor levels in a large number of subjects and cor-
related the levels of the inhibitor with the existence and
extent of coronary artery disease as well as with coronary
risk factors .
Methods
Subjects. Peripheral blood samples from 75 patient s (74
men and I woman, aged 33 to 85 years) with a chest pain
syndrome who were undergoing diagnostic coronary angi-
ography were assayed for tissue plasminogen activator
(t-PA) inhibitor levels. The extent of coronary atheroscle-
rosis in these subjects was graded on a scale of 0 to 3
depending on the number of vessels with a luminal diameter
reduction of greater than 50%.
Plasma samples from 24 outpatients (aged 34 to 72 years)
with clinically documented coronary artery disease (pre-
vious history of myocardial infarction, positive exercise stress
test or unstable angina ) were also assayed for the inhibitor
levels. Plasma samples from 5 pediatric subjects (aged 5 to
I7 years) and from 10 health y, normal laboratory personnel
(aged 25 to 54 years) were also examined.
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Measurement of the inhibitor of tissue-plasminogen
activator (t-PA). Peripheral venous blood samples were
collected from all subjects in trisodium citrate only between
8:00 and 9:00 A .M. becau se diurnal variation has been de-
scribed in the plasma levels of the inhibitor (10). Blood was
centrifuged at 4°C for 20 minutes at 1,500 g and plasma
stored at - 70°C. The plasma levels of the inhibitor were
measured by an amidol ytic assay using purified t-PA and a
chromogenic substrate (3, 10). In brief. t-PA is added to
multiple dilution s of plasma , and residual t-PA activity is
subsequently determined using the plasmin substrate p-Val-
Leu-Lys-p-nitroan iline (52251), a gift from Kabi-Vitrum
AB, Stockholm . Plasmin inhibitors such as alpha s-anti-
plasmin and alpha--macroglobulin are destroyed by acidi-
fication. One unit of the inhibitor is the amount inhibiting
one unit of t-PA in this system.
Coronary risk factors . Serum levels of total choles-
terol, triglycerides and uric acid were measured by standard
enzymatic method s after a 12 hour fast in the 75 patient s
undergoing cardiac catheterizat ion . The subjects were con-
sidered hyperten sive if the supine diastolic blood pressure
was greater than 90 mm Hg on at least two occasions.
Smoking history, expre ssed as pack-years. was obtained by
personal interview with the patients. Patients were consid-
ered to have diabetes mellitu s if they were taking hypogly-
cemic agent s or if they had been previously told they were
diabetic and were treated with dietary control.
Statistical analysis. Group differences between patients
with and without significant coronary atherosclerosis were
tested for significance by the nonparametric Kruskal -Walli s
one-way analysis of variance and the Mann-Whitney test.
The relation between plasma levels of the t-PA inhibitor
and coronary risk factors was examined by conventional
linear regression analysis.
Results
Plasma tissue-plasminogen activator (t-PA) inhibitor
levels. The data on the 75 patients with angiographic evi-
dence of absence or presence (as well as extent) of coronary
atherosclerosis are presented in Table I . In these subgroups
of patients with similar age but different extent of disease ,
t-PA inhibitor levels were not significantly different (p =
NS). Serum levels of triglyceride, total cholesterol and uric
acid as well as smoking pattern and prevalence of hyper-
tension and diabetes mellitus were similar in these subgroups
of patients. The t-PA inhibitor levels in patients with clinical
evidence of coronary artery disease (3.02 ± 1.51 units/ml ,
mean ± SD) were also in the same range as in the patients
undergoing coronary angiograph y (Fig. I). However, com-
pared with levels in healthy, normal laboratory personnel
(mean 0.99 ± 0.64 units/ml) and pediatric subjects (mean
1.17 ± 0.95 units/rnl), t-PA inhibitor levels in patients with
clinically or angiographically documented coronary disease
were significantly (p < 0.02) increased .
Plasma tissue-plasminogen activator (t·PA) inhibitor
levels and coronary risk factors. The t-PA inhibitor levels
correlated significantly with age (Fig. 2) (r - 0 .46, P <
0.005 ), rising in older patients and were also correlated
significantly with serum triglyceride levels (Fig. 3) (r -
Table 1. Angiographic Extent of Coronary Artery Disease , Tissue-Plasminogen Activator (t-PA)
Inhibitor Levels and Coronary Artery Disease Risk Factors in 75 Patients Undergoing
Coronary Angiography
CAD Severity (no. of vessels diseased)
0 2 3
No. of patients 14 I I 2 1 29
Age (yr) 56 ± 12 56 ± 7 58 ± 8 61 ± 8
Weight (kg) 79.7 ± 16.2 87.3 ::': 11.3 79.2 ± 10.4 79.7 ± 10.4
Plasma t-PA 2.5 ± 1.4 2.2 ::': 1.6 2.2 ± 1.7 2.2 ::': 1.4
inhibitor
(units/nil)
Serum triglycerides 3 10 ± 196 231 ::': 150 220 ± 254 192 ± 59
(mg/dl )
Serum cholesterol 186 ± 54 200 ::': 104 20 1 ± 49 175 ± 40
(mg/dl)
Serum uric acid 5.8 ± 2.0 8.0 ± 2.2 5.9 ± 0 .8 6.1 ± 2.5
(mgldl)
Smok ing (pack-y r) 39 ± 14 45 ::': 31 42 ::': 12 37 ± 16
Hypertension (no. 7 7 10 18
of patients)
Diabetes mellitu s 2 2 4 8
(no . of patients)
Data expressed as mean values ± SD: CAD = coronary artery disease.
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Figure I. Tissue-plasminogen acti-
vator (t-PA) inhibitor levels in 10young
norm al subjects (mean age 26 years).
75 patients with chest pain undergoing
angiography (mean age 57 years) and
24 patients with clinical coro nary ar-
tery disease (CAD) (mean age 58
years). Plasma t-PA inhibitor levels
were significantly higher in the older
patients than in the youn ger normal
subjects.
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0.60, P < 0.001). There was, however, no correlation be-
tween t-PA inhibitor levels and the serum concentrations of
total cholesterol (Fig. 4), uric acid, patients' body weight,
history of smoking, presence of hypertension or diabetes
mellitus. The mean plasma value of the t-PA inhibitor was
2.57 ± 1.47 units/ml in normotensive subjects and 2.14 ±
1.44 units/ml in hypertensive subjects (p = NS). It was
2.32 ± 1.47 units/ml in patients without diabetes mellitus
and 1.96 ± 1.41 units/ml in patients with diabetes mellitus
(p = NS).
Discussion
Age and t-PA inhibitor. The results of our study dem-
onstrate that patients with coronary artery disease have higher
plasma levels of tissue-plasminogen activator (t-PA) inhib-
itor than do young normal, healthy subjects, and that the
plasma levels of the inhibitor do not vary with the extent
of the disease (7) . Furthermore. we found no significant
difference between age-matched patients with chest pain
without significant coronary disease and others with signif-
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Figure 2. Positive corre lation be-
tween age and plasma t-PA inhibitor
levels (r - 0.46, P < 0 .005 ).
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Figure 3. Positive correlation be-
tween serum triglyceride levels and
plasma t-PA inhibitor levels (r - 0.60,
P < 0.00 1).
icant disease relative to the plasma levels of t-PA inhibitor.
These data strongly suggest that high levels oft-PA inhibitor
are not primaril y associated with coronary disease. Never-
theless, we found a significant correlation between the plasma
levels of t-PA inhibitor and age of the subjects. Because
the patients with coronary artery disease are generally older
than those without disease, age is probably a contributory
factor to the difference in t-PA inhibitor levels observed
previously.
An influence of age on defective fibrinolysis as deter-
mined by the dilute blood clot lysis time has earlier been
reported , but the results are conflicting. Chakrabarti et al.
(9) initially described an increase in fibrinolytic activity with
age in patients with coronary artery disease. However , these
investigators ( I I) later found reduction in fibrinolytic ac-
tivity after analysis of a large number of such patients. The
clot lysis time used by these investigators is nonspecific and
dependent on both plasminogen activators and various fi-
brinolysis inhibitors .
Serum triglycerides and tissue-plasminogen activator
(t-PA) inhibitor. Another factor that may have contributed
to the increased plasma levels of t-PA inhibitor in our pa-
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tients undergoing coronary angiography is the significant
prevalence of hypertriglyceridemia. The correlation be-
tween high levels of triglycerides and t-PA inhibitor found
in the present investigation confirms similar observations
made previously by us (10) and recently by Hamsten et al.
(12). Although our results suggest that t-PA inhibitor is not
of pathogenetic importance for coronary artherosclerosis, it
is possible that hypertriglyceridemia may contribute to coro-
nary thrombosis by inducing an increase in t-PA inhibitor
levels, especially in elderly patients. That an increase in
t-PA inhibitor may be secondary to the increase in triglyc-
erides is favored by the demonstrated association of dietary
regulation of triglycerides and increased fibrinolytic activity
(13), which may be due to a reduction in t-PA inhibitor
levels. At present, however, we cannot exclude a common
factor, such as increased levels of catecholamines (12), which
may cause elevation of both serum triglycerides and t-PA
inhibitor levels, particularly in patients under stress. None-
theless, coronary thrombosis may relate to reduced fibrin-
olytic activity, which has been found in patients with coro-
nary artery disease who later died (14). Reduced fibrinolytic
activity has also been associated with graft occlusion in
patients undergoing aortocoronary bypass surgery (15).
Tissue-plasminogen activator (t-PA) inhibitor and fi-
brinolysis. Inhibitor of t-PA is probably produced by endo-
thelial cells (16) as well as in platelets (17). Increased levels
of this inhibitor were found in patients with the adult res-
piratory distress syndrome after trauma and sepsis (18),
possibly related to endotoxin-induced release of t-PA in-
hibitor from the endothelial cells (5). A high level of t-PA
inhibitor seems also to be responsible for the impaired fi-
brinolytic response to venous occlusion found in patients
with deep venous thrombosis (19), related probably to rapid
inactivation of the released t-PA by the inhibitor. The t-PA
inhibitor rapidly forms a stable, inactive complex with
t-PA (20) and this mechanism may be of importance for
delayed fibrin degradation and development of thrombosis.
A protraction of whole blood and plasma clot lysis in pa-
tients with naturally occurring high levels of t-PA inhibitor
which suggests a pathophysiologic significance of t-PA in-
hibitor in fibrinolysis and thrombolysis, was recently dem-
onstrated (21). An in vivo effect of t-PA inhibitor on fibrin
degradation and thrombolysis, however. has yet to be proved.
Interestingly, an identical impaired response to fibrinolytic
stimulus found in patients with thrombosis and high levels
of the t-PA inhibitor (19) was demonstrated in patients with
hypertriglyceridemia (22), further suggesting a connection
between triglycerides, t-PA inhibitor, and thrombosis.
Normal values of tissue-plasminogen activator (t-PA)
inhibitor. An international standard for t-PA inhibitor is
not yet available, and the levels obtained in healthy, normal
subjects differ among various laboratories. Mean values of
1.5 ± 0.7 (7), 0.46 ± 0.50 (8) and 0.7 ± 0.7 units/ml
(23) have been reported. Plasma t-PA levels reported in
patients with coronary artery disease range from 0.80 ±
I. 19 (8) to 3.1 ± I.2 units/ml (7). These differences can
partly be explained by variations in age and triglyceride
levels, and also by the diurnal change in the inhibitor levels
(10). They could also be due to lack of uniformity in assays
for measurement of the inhibitor; for example, it has been
reported that the rate of inhibition of t-PA increases with
the amount of t-PA added to plasma (24).
Conclusions. Hypertriglyceridemia, especially in el-
derly patients with coronary artery disease, is associated
with increased plasma levels oft-PA inhibitor. This increase
in the t-PA inhibitor levels might be of importance in the
evolution of coronary thrombosis in these patients and could
possibly be involved in the impaired response to t-PA treat-
ment of coronary thrombosis in some patients. The fact that
no difference in t-PA inhibitor levels was found between
age-matched patients with and without coronary artery dis-
ease (and variable extent) speaks against, but does not ex-
clude, an important role for t-PA in the development of
coronary atherosclerosis.
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